Levaquin, Quinsair(levofloxacin)
Iquix, Levaquin, Quinsair, Quixin (levofloxacin) is a small molecule pharmaceutical. Levofloxacin was first approved as Levaquin on 1996-12-20. It is used to treat bacterial eye infections, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bronchitis amongst others in the USA. It has been approved in Europe to treat cystic fibrosis and respiratory tract infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Levofloxacin (discontinued: Iquix, Levaquin, Levofloxacin, Quixin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levofloxacin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LEVAQUIN | Johnson & Johnson | N-020634 DISCN | 1996-12-20 | 3 products, RLD |
| LEVAQUIN | Johnson & Johnson | N-020635 DISCN | 1996-12-20 | 1 products, RLD |
| LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER | Johnson & Johnson | N-020635 DISCN | 1996-12-20 | 2 products, RLD |
| LEVAQUIN | Johnson & Johnson | N-020635 DISCN | 1996-12-20 | 1 products, RLD |
| LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER | Johnson & Johnson | N-020635 DISCN | 1996-12-20 | 1 products, RLD |
| LEVAQUIN | Johnson & Johnson | N-021721 DISCN | 2004-10-21 | 1 products, RLD |
| IQUIX | Santen | N-021571 DISCN | 2004-03-01 | 1 products, RLD |
| QUIXIN | Santen | N-021199 DISCN | 2000-08-18 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| levaquin | ANDA | 2020-11-23 |
| levofloxacin | ANDA | 2025-01-14 |
| ofloxacin | ANDA | 2024-12-16 |
| ofloxacin ophth soln | ANDA | 2023-05-22 |
Indications
FDA
EMA
Show 12 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD10: Lansoprazole, amoxicillin and levofloxacin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01M: Quinolone antibacterials
— J01MA: Fluoroquinolone antibacterials, systemic
— J01MA12: Levofloxacin
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA05: Levofloxacin and ornidazole
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AE: Fluoroquinolone antiinfectives, ophthalmologic
— S01AE05: Levofloxacin
HCPCS
Code | Description |
|---|---|
| J1956 | Injection, levofloxacin, 250 mg |
Clinical
Clinical Trials
418 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cataract | D002386 | HP_0000518 | H26.9 | — | — | — | 1 | — | 1 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | — | — | 1 | — | 1 |
| Dry eye syndromes | D015352 | — | H04.12 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Levofloxacin |
| INN | levofloxacin |
| Description | Levofloxacin is an optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase. It has a role as a DNA synthesis inhibitor, an antibacterial drug, a topoisomerase IV inhibitor and an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor. It is a quinolone antibiotic, a fluoroquinolone antibiotic and a 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid. It is an enantiomer of a dextrofloxacin. |
| Classification | Small molecule |
| Drug class | antibacterials (quinolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23 |
Identifiers
| PDB | — |
| CAS-ID | 100986-85-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL33 |
| ChEBI ID | 63598 |
| PubChem CID | 149096 |
| DrugBank | DB01137 |
| UNII ID | RIX4E89Y14 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Quinsair – Horizon Therapeutics Public
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Levofloxacin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 43,286 documents
View more details
Safety
Black-box Warning
Black-box warning for: Levofloxacin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
129,075 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use